Evidence map›Paper›PMID 37894361›Full record

ArticleCancers2023

Polyploid Giant Cancer Cells Generated from Human Cytomegalovirus-Infected Prostate Epithelial Cells.

Fidaa Bouezzedine, Ranim El Baba, Sandy Haidar Ahmad, Georges Herbein

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Fidaa BouezzedinePathogens & Inflammation/EPILAB Laboratory, EA 4266, University of Franche-Comté, 25000 Besançon, France.
Ranim El BabaPathogens & Inflammation/EPILAB Laboratory, EA 4266, University of Franche-Comté, 25000 Besançon, France.ORCID 0000-0002-2984-5870
Sandy Haidar AhmadPathogens & Inflammation/EPILAB Laboratory, EA 4266, University of Franche-Comté, 25000 Besançon, France.ORCID 0000-0001-5375-0874
Georges HerbeinPathogens & Inflammation/EPILAB Laboratory, EA 4266, University of Franche-Comté, 25000 Besançon, France.
Université de franche-comté · FR

Funding

Ligue Nationale contre le Cancer CR3304Région Franche comté 2021-Y-08292 and 2021-Y-08290University of Franche-Comté CR3300
6 · The paper itself

Abstract

backgroundProstate cancer is the most commonly diagnosed malignancy and the sixth leading cause of cancer death in men worldwide. Chromosomal instability (CIN) and polyploid giant cancer cells (PGCCs) have been considered predominant hallmarks of cancer. Recent clinical studies have proven the association of CIN, aneuploidy, and PGCCs with poor prognosis of prostate cancer (PCa). Evidence of HCMV transforming potential might indicate that HCMV may be involved in PCa.

methodsHerein, we underline the role of the high-risk HCMV-DB and -BL clinical strains in transforming prostate epithelial cells and assess the molecular and cellular oncogenic processes associated with PCa.

resultsOncogenesis parallels a sustained growth of "

conclusionsHCMV-induced Myc and EZH2 upregulation coupled with stemness and EMT traits in IE1-expressing CTP might highlight the potential role of HCMV in PCa development and encourage the use of anti-EZH2 and anti-HCMV in PCa treatment.

Indexed as

CINhigh-risk HCMV strainshuman cytomegalovirusoncogenesisPGCCsprostate cancerstemness

Identifiers

PMID37894361
PMCPMC10604969
OpenAlexW4387653562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.